Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma

被引:53
作者
Sun, T
Miao, XP
Wang, JW
Tan, W
Zhou, YF
Yu, CY
Lin, DX [1 ]
机构
[1] Chinese Acad Med Sci, Dept Etiol & Carcinogenesis, Canc Inst & Hosp, Beijing 100021, Peoples R China
[2] Chinese Acad Med Sci, Dept Surg, Canc Inst & Hosp, Beijing 100021, Peoples R China
[3] Peking Union Med Coll, Beijing 100021, Peoples R China
关键词
D O I
10.1093/carcin/bgh244
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aurora-A/BTAK/STK15, involved in regulating centrosomes and chromosome segregation, is overexpressed in human breast carcinoma and other cancers. The Phe31-->Ile polymorphism in Aurora A alters the kinase function, with the Ile31 variant being preferentially amplified and associated with degree of aneuploidy in human tumors. We have previously shown that the Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal cancer. This case-control study examined the contribution of this polymorphism to susceptibility to development and progression of breast cancer. Aurora A genotypes were determined in 520 patients with breast carcinoma, 191 patients with benign breast diseases (BBD) and 520 controls. It was found that the Aurora A Ile/Ile genotype was significantly associated with increased risk of breast carcinoma occurrence [odds ratio (OR) 1.66; 95% confidence interval (95% CI) 1.29-2.12] compared with the Phe/Phe or Phe/Ile genotype. The increased risk for BBD and breast carcinoma related to the Ile/Ile genotype was more pronounced in younger subjects. Moreover, we found that patients carrying the Ile/Ile genotype tended to have ER-carcinomas (OR 2.56; 95% CI 1.24-5.26). No significant association was observed between the polymorphism and metastasis and disease stage of the cancer. These findings suggest that the Phe31Ile polymorphism in Aurora A may be a genetic modifier for developing breast carcinoma.
引用
收藏
页码:2225 / 2230
页数:6
相关论文
共 43 条
[1]   Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients [J].
Barnes, DM ;
Harris, WH ;
Smith, P ;
Millis, RR ;
Rubens, RD .
BRITISH JOURNAL OF CANCER, 1996, 74 (09) :1445-1451
[2]   A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers [J].
Bischoff, JR ;
Anderson, L ;
Zhu, YF ;
Mossie, K ;
Ng, L ;
Souza, B ;
Schryver, B ;
Flanagan, P ;
Clairvoyant, F ;
Ginther, C ;
Chan, CSM ;
Novotny, M ;
Slamon, DJ ;
Plowman, GD .
EMBO JOURNAL, 1998, 17 (11) :3052-3065
[3]   Prognostic and predictive factors in breast cancer [J].
Bundred, NJ .
CANCER TREATMENT REVIEWS, 2001, 27 (03) :137-142
[4]   The cellular geography of aurora kinases [J].
Carmena, M ;
Earnshaw, WC .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (11) :842-854
[5]  
CLARK GM, 1988, SEMIN ONCOL, V15, P20
[6]   Risk factors for breast cancer according to estrogen and progesterone receptor status [J].
Colditz, GA ;
Rosner, BA ;
Chen, WY ;
Holmes, MD ;
Hankinson, SE .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (03) :218-228
[7]   The centrosome - a tiny organelle with big potential [J].
Doxsey, S .
NATURE GENETICS, 1998, 20 (02) :104-106
[8]   On the role of aurora-A in centrosome function [J].
Dutertre, S ;
Descamps, S ;
Prigent, C .
ONCOGENE, 2002, 21 (40) :6175-6183
[9]   Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human [J].
Ewart-Toland, A ;
Briassouli, P ;
de Koning, JP ;
Mao, JH ;
Yuan, JW ;
Chan, F ;
MacCarthy-Morrogh, L ;
Ponder, BAJ ;
Nagase, H ;
Burn, J ;
Ball, S ;
Almeida, M ;
Linardopoulos, S ;
Balmain, A .
NATURE GENETICS, 2003, 34 (04) :403-412
[10]  
FORD D, 1995, AM J HUM GENET, V57, P1457